Given its promising in vitro activity, exarafenib was advanced into in vivo studies focusing on lung cancer, using cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) models of BRAF-mutated human cancers. The gene discussed is BRAF; the disease is lung carcinoma.